Scarica l'app Stockscreener
15.32
4.31%
-0.69
Dopo l'orario di chiusura:
14.87
-0.45
-2.94%
Precedente Chiudi:
$16.01
Aprire:
$15.745
Volume 24 ore:
1.22M
Relative Volume:
0.37
Capitalizzazione di mercato:
$1.28B
Reddito:
-
Utile/perdita netta:
$-15.28M
Rapporto P/E:
-30.27
EPS:
-0.5061
Flusso di cassa netto:
$-32.97M
1 W Prestazione:
-3.01%
1M Prestazione:
-17.90%
6M Prestazione:
+162.78%
1 anno Prestazione:
+240.44%
Intervallo 1D:
$14.59
$16.44
Intervallo di 1 settimana:
$14.59
$17.07
Portata 52W:
$2.54
$26.95
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Nome
Corvus Pharmaceuticals Inc
Settore
Industria
Telefono
(650) 900-4520
Indirizzo
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA
Compare CRVS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
15.32 | 1.28B | 0 | -15.28M | -32.97M | -0.5061 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-01-02 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-18 | Iniziato | Oppenheimer | Outperform |
| 2021-12-01 | Ripresa | Jefferies | Buy |
| 2021-05-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-02-10 | Downgrade | Mizuho | Buy → Neutral |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-05-29 | Iniziato | ROTH Capital | Buy |
| 2017-08-24 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | Iniziato | Credit Suisse | Outperform |
| 2016-04-18 | Iniziato | Guggenheim | Buy |
Mostra tutto
Corvus Pharmaceuticals Inc Borsa (CRVS) Ultime notizie
Corvus Pharmaceuticals Bets Big on Soquelitinib Pipeline - TipRanks
CRVS Stock Receives Analyst Rating and Price Target Boost from O - GuruFocus
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Rapid Multi‑Year Share Price Gains - Yahoo Finance
According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), Corvus Pharmaceuticals, Inc. has signed a revised equity distribution agreement. - Bitget
Corvus Pharmaceuticals Expands ATM Equity Program to $200 Million With Jefferies - TradingView
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2025 Earnings Call Transcript - Insider Monkey
Corvus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Corvus Pharmaceuticals (CRVS) files S-3 shelf to offer stock, debt, warrants - Stock Titan
Oppenheimer raises Corvus Pharmaceuticals stock price target to $33 By Investing.com - Investing.com Canada
Corvus Trials Progress And Cash Raise Reframe Soquelitinib Risk Reward Profile - simplywall.st
Corvus: Q4 Earnings Snapshot - theheraldreview.com
Decoding Corvus Pharmaceuticals Inc (CRVS): A Strategic SWOT Ins - GuruFocus
Corvus: Fourth Quarter Earnings Overview - Bitget
Earnings call transcript: Corvus Pharmaceuticals Q4 2025 Misses EPS Forecast - Investing.com
CRVS: Strong clinical and financial momentum with soquelitinib, supporting pipeline expansion and durability - TradingView
Corvus Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Corvus Pharmaceuticals 2025 Financial Report: Quarterly & Annual Results | CRVSNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Corvus Pharmaceuticals rises on atopic dermatitis trial data By Investing.com - Investing.com Australia
Corvus Pharmaceuticals rises on atopic dermatitis trial data - Investing.com South Africa
CORVUS PHARMACEUTICALS ($CRVS) Releases Q4 2025 Earnings - Quiver Quantitative
Corvus Pharmaceuticals (NASDAQ: CRVS) highlights soquelitinib Phase 3 and Phase 2 trials - Stock Titan
Corvus Pharmaceuticals 10‑K: $0 Revenue, $(0.19) EPS (basic) — net loss $(15.28M) - TradingView
Corvus eczema drug posts positive early data and $189M cash boost - Stock Titan
Corvus Pharmaceuticals earnings on deck after positive trial data By Investing.com - Investing.com South Africa
Corvus Pharmaceuticals earnings on deck after positive trial data - Investing.com India
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Quarterly Earnings: Is Corvus Pharmaceuticals Inc being accumulated by smart money2026 Technical Overview & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Corvus Pharmaceuticals (CRVS) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Corvus Pharmaceuticals (CRVS) hits all-time high on eczema trial results - MSN
Fed Meeting: Does Corvus Pharmaceuticals Inc outperform in volatile marketsStop Loss & Fast Entry Momentum Alerts - baoquankhu1.vn
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 - The Manila Times
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 9.4%Here's Why - MarketBeat
Corvus Advances Soquelitinib Into Phase 2 Eczema Trial: What Investors Should Watch - TipRanks
Biotech Corvus sets March 12 call to discuss its 2025 results - Stock Titan
Does Corvus Pharmaceuticals’ (CRVS) Soquelitinib Focus Clarify Its Core Strategy or Concentration Risk? - simplywall.st
Market Recap: Is Corvus Pharmaceuticals Inc stock forming a cup and handle2025 Earnings Surprises & Consistent Return Investment Signals - baoquankhu1.vn
Assessing Corvus Pharmaceuticals (CRVS) Valuation After New Soquelitinib Trial Plans And Atopic Dermatitis Data - Sahm
Corvus Pharmaceuticals Highlights Soquelitinib Pipeline, Eyes Phase II Atopic Dermatitis Trial in 2026 - MarketBeat
Corvus Pharmaceuticals at Oppenheimer: Soquelitinib’s Promising Potential By Investing.com - Investing.com Canada
Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Yahoo Finance
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 7.6%Time to Sell? - MarketBeat
Corvus Pharmaceuticals, Inc. $CRVS Shares Bought by GSA Capital Partners LLP - MarketBeat
Is Corvus Pharmaceuticals (CRVS) Still Attractive After Its Recent Share Price Surge - Yahoo Finance
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Corvus Pharmaceuticals (CRVS) Valuation Check After A Sharp Biotech Share Price Surge - Sahm
Is Corvus Pharmaceuticals (CRVS) Still Attractive After A 185% Monthly Surge? - simplywall.st
Corvus Pharmaceuticals (CRVS) price target increased by 128.26% to 35.70 - MSN
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data - AOL.com
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026 - Investing.com
Commit To Buy Corvus Pharmaceuticals At $8, Earn 20% Using Options - Nasdaq
Corvus Pharmaceuticals Inc Azioni (CRVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):